ImmunityBio (IBRX) Cash & Equivalents (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Cash & Equivalents of $205.2 million for Q1 2026, up 238.27% year-over-year from $60.7 million in Q1 2025, and up 132.29% quarter-over-quarter from $88.3 million in Q4 2025.
ImmunityBio (IBRX) Cash & Equivalents (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Cash & Equivalents for 13 consecutive years, with $205.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents rose 238.27% year-over-year to $205.2 million; the TTM figure through Mar 2026 stood at $205.2 million (up 238.27% YoY), while the FY2025 annual figure was $88.3 million, down 38.41% from the prior year.
- Cash & Equivalents climbed to $205.2 million in Q1 2026 per IBRX's latest filing, from $88.3 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $265.5 million in Q4 2023 and bottomed at $36.4 million in Q1 2022.
- Historically, Cash & Equivalents has averaged $114.9 million across 5 years, with a median of $104.6 million in 2022.
- Annual changes were most pronounced in 2025 — Cash & Equivalents plunged 54.4% — and 2026, when it jumped 238.27%.
- ImmunityBio's Cash & Equivalents stood at $104.6 million in 2022, then jumped by 153.68% to $265.5 million in 2023, then slumped by 45.97% to $143.4 million in 2024, then plunged by 38.41% to $88.3 million in 2025, then soared by 132.29% to $205.2 million in 2026.
- Business Quant data shows IBRX's Cash & Equivalents at $205.2 million in Q1 2026, $88.3 million in Q4 2025, and $60.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | 75.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 75.67 Mn |
| Mar 31, 2026 | 205.19 Mn |
| Dec 31, 2025 | 88.33 Mn |
| Sep 30, 2025 | 60.24 Mn |
| Jun 30, 2025 | 137.66 Mn |
| Mar 31, 2025 | 60.66 Mn |
| Dec 31, 2024 | 143.43 Mn |
| Sep 30, 2024 | 111.97 Mn |
| Jun 30, 2024 | 130.10 Mn |
| Mar 31, 2024 | 133.04 Mn |
| Dec 31, 2023 | 265.45 Mn |
| Sep 30, 2023 | 177.96 Mn |
| Jun 30, 2023 | 43.51 Mn |
| Mar 31, 2023 | 88.48 Mn |
| Dec 31, 2022 | 104.64 Mn |
| Sep 30, 2022 | 104.16 Mn |
| Jun 30, 2022 | 61.90 Mn |
| Mar 31, 2022 | 36.39 Mn |
| Dec 31, 2021 | 181.10 Mn |
| Sep 30, 2021 | 64.52 Mn |